At the 6th International Cell & Gene Therapy China Summit & Exhibition (CGCS2025), GENOMBIO, a company with over two decades of deep engagement in cell technology, once again received high honors. Its stable CMC and quality solutions were awarded the “Rising Star Award for Stable CMC and Quality Solutions in the CGT Field.” This award fully demonstrates the industry’s strong recognition of GENOMBIO’s outstanding contributions to key supporting technologies in cell and gene therapy.
This year’s exhibition grandly opened on May 29 in Nanjing, Jiangsu Province. GENOMBIO made a strong appearance, fully demonstrating its entire industry chain layout in the biomedical and health sector. The booth attracted large crowds, and many professionals stopped to communicate and engage in heated discussions around GENOMBIO’s cutting-edge technologies and solutions.
Core Product Matrix: Comprehensive Support from Basic Research to Clinical Application
The star product lines GENOMBIO showcased precisely cover key processes in the cell & gene therapy (CGT) pipeline, from basic research and clinical translation to healthcare applications:
01 The Cornerstone of Cell Culture:
Serum-free Cell Culture Solutions: GENOMBIO has developed specialized serum-free media and matched cryopreservation solutions for various cell types (such as MSC, NK, T, CIK, 293, etc.). These products, with well-defined chemical composition, high batch-to-batch stability, and standardized manufacturing, effectively solve the core needs for consistency and safety in cell culture for both research and industry. They have been widely adopted by research institutes and early-stage development projects, laying a strong technical foundation for the development of downstream cell therapy products.
Fetal Bovine Serum: As a classic component in traditional cell culture, GENOMBIO provides high-quality, strictly quality-controlled fetal bovine serum products.
02 Enabler for Cutting-edge Research & Drug Development:
Matrix Gel and Organoid Technology Platform: GENOMBIO provides high-quality AugNord (ORG) matrix gel (Orgmatrix gel) combined with advanced organoid culture technology, building a strong in vitro model platform. This platform can simulate the structure and function of human organs/tissues at a high level, providing a revolutionary tool for high-throughput drug screening, precise drug efficacy/toxicity evaluation, disease mechanism research, and personalized medicine—significantly accelerating new drug R&D and translational medicine.
03 Innovative Practices in Health Empowerment by Cell Technology:
GENOMBIO actively extends its core cell technologies into health management, showcasing the core technologies and products behind its “Prevention-Intervention-Repair” health management concept:
Core Cell Technologies: Cover cell storage, cell testing, cell preparation, cell therapy, cell products, health management projects, as well as the “Hi Doctor” brand focusing on male and female reproductive health.
Health Function Products: GENOM Health introduced the “Lung Shukang” nano-vesicle solution, focusing on respiratory health. The “Jiejiu Soup” by Bo Yao Tang, utilizing the “medicine-food homology” concept alongside modern processes, offers liver protection—demonstrating “technology + tradition” fusion innovation.
Accumulated Strength, Full Industry Chain Layout Leads Development
GENOMBIO (GENOM Life & Health Holdings Group) was founded in February 2002, with its headquarters in ZJU Zijin Creative Town, Xihu District, Hangzhou. After over 20 years of development, the group has built a comprehensive biomedical and health industry chain covering seed cell banks, cell culture reagents and consumables, cell storage, cell therapy drug development, stem cell exosome applications, laboratory technical services, organoid products and services.
The group operates 10 wholly owned subsidiaries—Zhejiang GENOM CyberBio, Zhejiang Xinuo Juncare Bio, Hangzhou GENOM Biopharmaceuticals, Anhui GENOM Cell Bio, Shanghai AugNord Bio, Shanghai GENOM Cell Stem Cells, Anhui Bo Yao Tang Traditional Chinese Medicine Science and Technology, etc.—forming a powerful network for R&D, production, sales, and technical services. As a national high-tech enterprise group, GENOMBIO always upholds its mission of “using cell technology to safeguard life and health.” Its core values—“customer first, striving-oriented, unity and collaboration, co-creation for all-win”—drive ongoing innovation.
Winning the “Rising Star Award” at CGCS2025 is not only authoritative recognition of GENOMBIO’s technical strength in CMC and quality management in the CGT field, but also a comprehensive affirmation of its industry chain-wide R&D and industrialization capabilities in cell technology. GENOMBIO will continue to deepen its engagement in cell technology, firmly pursue the vision of becoming a “leading brand in the full cell industry chain,” and contribute core strength to the development of the global biopharmaceutical industry and the health sector.